Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Quadrivalent Seasonal Influenza Candidate Vaccine GSK2321138A, Administered to Children Who Previously Participated in Study 115345
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2017
At a glance
- Drugs GSK 2321138A (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 05 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Sep 2013 New source identified and integrated (United Kingdom Clinical Research Network, 13386).
- 23 Mar 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2012-001230-34).